ABAXIS, INC. (NASDAQ:ABAX) Files An 8-K Results of Operations and Financial Condition

0

ABAXIS, INC. (NASDAQ:ABAX) Files An 8-K Results of Operations and Financial Condition

Item 2.02

Results of Operations and Financial Condition.
The information in this Item 2.02, including the exhibit attached
hereto, is being furnished and shall not be deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended or the Exchange Act, or otherwise subject to the
liabilities of that Section. The information in this Item 2.02
shall not be deemed incorporated by reference into any filing
under the Securities Act of 1933, as amended, or the Exchange Act
regardless of any general incorporation language in such filing.
On April 27, 2017, Abaxis, Inc. announced its financial results
for the fourth quarter and fiscal year ended March 31, 2017 and
certain other financial information. A copy of Abaxis press
release announcing these financial results and certain other
financial information is attached hereto as Exhibit 99.1 and is
incorporated by reference herein.
Item 8.01
Other Events.
On April 26, 2017, the Board of Directors of Abaxis, Inc.
declared a quarterly cash dividend of $0.14 per common share, to
be paid on June 15, 2017 to all shareholders of record as of the
close of business on June 1, 2017.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
The following exhibit is furnished with this report on Form 8-K:
Exhibit No.
Description
99.1
Press release dated April 27, 2017


About ABAXIS, INC. (NASDAQ:ABAX)

Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force. The Company’s segments are the medical market and the veterinary market. The Company’s medical market products include Piccolo chemistry analyzers and consumable products. The Company develops, manufactures and sells the Piccolo Xpress chemistry analyzer for use in human patient care to provide clinicians with blood constituent measurements. The Company’s veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs, VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i-STAT analyzers and related consumables and VetScan rapid tests.

ABAXIS, INC. (NASDAQ:ABAX) Recent Trading Information

ABAXIS, INC. (NASDAQ:ABAX) closed its last trading session up +0.14 at 49.35 with 91,665 shares trading hands.